Regeneron Pharmaceuticals Inc (REGN)
901.48
+7.34
(+0.82%)
USD |
NASDAQ |
Apr 17, 16:00
902.50
+1.02
(+0.11%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Investing (TTM): -3.185B for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -3.185B |
September 30, 2023 | -4.977B |
June 30, 2023 | -4.288B |
March 31, 2023 | -2.315B |
December 31, 2022 | -3.785B |
September 30, 2022 | -3.940B |
June 30, 2022 | -6.571B |
March 31, 2022 | -6.031B |
December 31, 2021 | -5.385B |
September 30, 2021 | -3.677B |
June 30, 2021 | -2.014B |
March 31, 2021 | -686.40M |
December 31, 2020 | -70.60M |
September 30, 2020 | 25.70M |
June 30, 2020 | 594.50M |
March 31, 2020 | -1.695B |
December 31, 2019 | -2.028B |
September 30, 2019 | -2.085B |
June 30, 2019 | -2.165B |
March 31, 2019 | -1.814B |
December 31, 2018 | -1.463B |
September 30, 2018 | -1.533B |
June 30, 2018 | -1.605B |
March 31, 2018 | -1.290B |
December 31, 2017 | -1.005B |
Date | Value |
---|---|
September 30, 2017 | -940.69M |
June 30, 2017 | -987.66M |
March 31, 2017 | -1.143B |
December 31, 2016 | -1.047B |
September 30, 2016 | -898.85M |
June 30, 2016 | -776.17M |
March 31, 2016 | -821.80M |
December 31, 2015 | -907.60M |
September 30, 2015 | -727.66M |
June 30, 2015 | -567.55M |
March 31, 2015 | -314.03M |
December 31, 2014 | -420.78M |
September 30, 2014 | -587.37M |
June 30, 2014 | -678.75M |
March 31, 2014 | -444.00M |
December 31, 2013 | -355.46M |
September 30, 2013 | -154.40M |
June 30, 2013 | 11.29M |
March 31, 2013 | -244.52M |
December 31, 2012 | -81.07M |
September 30, 2012 | -206.08M |
June 30, 2012 | -158.23M |
March 31, 2012 | 123.89M |
December 31, 2011 | 128.47M |
September 30, 2011 | -192.24M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-6.571B
Minimum
Jun 2022
594.50M
Maximum
Jun 2020
-2.857B
Average
-2.315B
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -3.142B |
Eli Lilly and Co | -7.153B |
CytomX Therapeutics Inc | -150.67M |
Pfizer Inc | -32.28B |
Puma Biotechnology Inc | -19.12M |